Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05943496
Title Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Newly Diagnosed Chronic Lymphocytic Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors OHSU Knight Cancer Institute
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
OHSU Knight Cancer Institute RECRUITING Portland Oregon 97239 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field